comparemela.com

Latest Breaking News On - Scientific sessions of the american diabetes association - Page 3 : comparemela.com

Endocrinology Month in Review: July 2023

Tirzepatide Further Cements Weight Loss Benefit in SURMOUNT-3 and SURMOUNT-4 Trials

On July 27, 2023, Eli Lilly and Company announced topline results of the SURMOUNT-3 and SURMOUNT-4 trials, with both trials achieving all primary endpoints of interest and full results scheduled to be presented later this year.

Once-Weekly Insulin Analogue Demonstrates Promising Results for Those With Type 2 Diabetes

Patients with type 2 diabetes receiving once-weekly insulin icodec were more likely to reach a hemoglobin A1C level below 7% compared to those who received once-daily insulin analogues.

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.